Information Provided By: 
Fly News Breaks for January 28, 2019
AGN, EOLS
Jan 28, 2019 | 16:23 EDT
Stifel analyst Annabel Samimy started Evolus (EOLS) with a Buy rating and $27 price target, citing her view of the potential for Jeuveau to be an identical, drop-in, "frictionless" replacement for Allergan's (AGN) Botox with "a marketing angle and pedigree that no other toxin has claimed before."
News For EOLS;AGN From the Last 2 Days
There are no results for your query EOLS;AGN
